Cargando…

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE

Detalles Bibliográficos
Autores principales:	Boeckle, D., Tabares, P., Zhou, X., Schimanski, S., Steinhardt, M. J., Bittrich, M., Seebacher, E., Ulbrich, M., Wilnit, A., Metz, C., Heidemeier, A., Bley, T., Werner, R., Buck, A., Einsele, H., Kortüm, M., Beilhack, A., Rasche, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429160/ http://dx.doi.org/10.1097/01.HS9.0000850756.31916.11

Ejemplares similares

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
por: Dahlhoff, Julia, et al.
Publicado: (2021)

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
por: Steinhardt, Maximilian J., et al.
Publicado: (2021)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
por: Munawar, U., et al.
Publicado: (2023)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials
por: Fleischer, Anna, et al.
Publicado: (2023)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

Editorial: The Involvement of NGF in the Alzheimer's Pathology
por: Cuello, A. Claudio
Publicado: (2019)

Expression of NGF/proNGF and Their Receptors TrkA, p75(NTR) and Sortilin in Melanoma
por: Marsland, Mark, et al.
Publicado: (2022)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

NGF and NGF-receptor expression of cultured immortalized human corneal endothelial cells
por: Sornelli, Federica, et al.
Publicado: (2010)

APP Regulates NGF Receptor Trafficking and NGF-Mediated Neuronal Differentiation and Survival
por: Zhang, Yun-wu, et al.
Publicado: (2013)

An Optimized Procedure for the Site-Directed Labeling of NGF and proNGF for Imaging Purposes
por: Di Matteo, Pierluigi, et al.
Publicado: (2017)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes
por: Steinhardt, M. J., et al.
Publicado: (2020)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

NGF : hacia una nueva frontera en la neurobiología /
por: Levi-Montalcini, Rita
Publicado: (1993)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

NGF – the TrkA to successful pain treatment
por: Kumar, Vinayak, et al.
Publicado: (2012)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NGF and proNGF Reciprocal Interference in Immunoassays: Open Questions, Criticalities, and Ways Forward
por: Malerba, Francesca, et al.
Publicado: (2016)

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan
por: Zhou, Xiang, et al.
Publicado: (2020)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Conformational Plasticity of proNGF
por: Paoletti, Francesca, et al.
Publicado: (2011)

NGF, Brain and Behavioral Plasticity
por: Berry, Alessandra, et al.
Publicado: (2012)

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA
por: Zhou, X., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qhsptupqosa8ve003mj70optbs